Regeneron Receives Another CRL for Eylea 8 mg
Regeneron faces another FDA setback for Eylea HD due to manufacturing issues.
The US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg, citing unresolved issues at the Bloomington, Indiana, plant of Novo Nordisk, Regeneron’s manufacturing partner.
- In August 2025, the FDA rejected a new blood cancer therapy due to problems at the same Novo Nordisk-owned site.
- Quality control lapses were found in November 2024, including a "pest" on the manufacturing line.
- The FDA tagged Novo's Indiana facility with an official action indicated (OAI) label.
Regeneron plans for new facilities signal future production improvements.
Author's summary: Regeneron faces FDA setbacks due to manufacturing issues.
More News
- Landry's Explosive Quote That Signals Major Changes at LSU
- Illinois House Democrats push first-in-the-world wealth tax, streaming, concert taxes
- Going Places: Discovery Bicycle Tours’ Vietnam: Hoi An’s Dazzling Lights, Tranquil Countryside
- Italian court rejects Sicily bridge project
- How to get the new Windows Start menu now